# Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

> **NCT02115321** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Elbasvir
- **DRUG:** MK-5172A

## Key facts

- **NCT ID:** NCT02115321
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-09
- **Primary completion:** 2015-03-05
- **Final completion:** 2015-06-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115321, "Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02115321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*